BeiGene
BGNE
#881
Rank
C$31.99 B
Marketcap
$285.95
Share price
-0.65%
Change (1 day)
4.07%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Cash on Hand

Cash on Hand as of June 2024 : C$3.60 Billion

According to BeiGene 's latest financial reports the company has C$3.60 Billion in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

BeiGene - Cash on Hand chart (from 2014 to 2024)

Cash on Hand by year

Year Cash on Hand Change
2023-12-31C$4.21 B-31.58%
2022-12-31C$6.15 B-27.04%
2021-12-31C$8.43 B42.22%
2020-12-31C$5.92 B362.01%
2019-12-31C$1.28 B-47.11%
2018-12-31C$2.42 B130.46%
2017-12-31C$1.05 B112.82%
2016-12-31C$0.49 B254.94%
2015-12-31C$0.13 B170.57%
2014-12-31C$51.51 M1132.75%
2013-12-31C$4.17 M

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
C$22.8 M-99.37%๐Ÿ‡บ๐Ÿ‡ธ USA
C$56.46 M-98.43%๐Ÿ‡บ๐Ÿ‡ธ USA